2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1096

Fibromyalgia Patients Who Have More Symptoms at Their Initial Office Visit Tend to Have a Worse Clinical Course
Abstract Number: 2056

Fibromyalgia Symptoms Beyond the Pain and Its Impact on the Patient
Abstract Number: 1982

Final Year Medical Students Prefer E-Reading Content to Interactive Case-Based Quizzes in a Pediatric Rheumatology E-Learning Module
Abstract Number: 918

Findings from Denosumab (Prolia^®) Postmarketing Safety Surveillance for Serious Infections
Abstract Number: 2015

Fine Particulate Air Pollution and Systemic Autoimmune Rheumatic Disease in Two Canadian Provinces
Abstract Number: 625

Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes
Abstract Number: 2918

Fine-Mapping Major Histocompatibility Complex Associations in ACPA-Positive Rheumatoid Arthritis Identified Shared HLA Amino Acid Polymorphisms in Asian and European Populations
Abstract Number: 511

First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Abstract Number: 457

First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Abstract Number: 2022

First Nations Persons Have an Increased Risk of Developing Rheumatoid Arthritis with an Early Onset Age but Are Seen Less Frequently By Rheumatologists: A Population Based Study
Abstract Number: 1837

First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis
Abstract Number: 905

First Step in the Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis: A Data Driven Approach
Abstract Number: 2667

First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy
Abstract Number: 2017

Fish Consumption and Risk of Rheumatoid Arthritis Among Women in Large Prospective Cohorts
Abstract Number: 1405

Five-Year Changes in Myocardial Structure and Function in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].